Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Inflammation × Clear all

Phase

Phase NA 13 Phase 4 2 Phase 3 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 33 Carcinoma, Hepatocellular 27 Neoplasms 19 Colorectal Neoplasms 18 Carcinoma, Non-Small-Cell Lung 17 Leukemia, Myeloid, Acute 16 Stomach Neoplasms 15 Prostatic Neoplasms 12 Lung Neoplasms 12 Colonic Neoplasms 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Rectal Neoplasms 10 Neoplasm Metastasis 8 Leukemia 8 Pancreatic Neoplasms 6 NSCLC 6 Multiple Myeloma 6 Liver Neoplasms 6 Esophageal Neoplasms 6 Small Cell Lung Carcinoma 4 Recurrence 4 Nasopharyngeal Carcinoma 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Head and Neck Neoplasms 4 Glioblastoma 4 Gestational Trophoblastic Disease 4 Esophageal Squamous Cell Carcinoma 4 Cholangiocarcinoma 4 Brain Neoplasms 4

Interventions

Dexmedetomidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡